Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme

PURPOSE: Evaluation of 1-year safety profile of intravitreal ranibizumab 0.5 mg in neovascular age-related macular degeneration (NV-AMD) within routine clinical practice. METHODS: The LUMINOUS programme comprises a prospective observational study assessing ranibizumab ‘real-world’ safety and clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Holz, Frank G, Bandello, Francesco, Gillies, Mark, Mitchell, Paul, Osborne, Aaron, Sheidow, Tom, Souied, Eric, Figueroa, Marta S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756427/
https://www.ncbi.nlm.nih.gov/pubmed/23850682
http://dx.doi.org/10.1136/bjophthalmol-2013-303232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756427/
https://www.ncbi.nlm.nih.gov/pubmed/23850682
http://dx.doi.org/10.1136/bjophthalmol-2013-303232

Ejemplares similares